In today’s briefing:
- Chugai Pharmaceutical (4519 JP): Positive Phase 3 Results Of Orforglipron Augurs Well
- BenQ BM Pre-IPO: PHIP Updates – Performance Continues to Deteriorate
- D. Western Therapeutics Institute (DWTI) 4576 JP – Full Report
Chugai Pharmaceutical (4519 JP): Positive Phase 3 Results Of Orforglipron Augurs Well
- Eli Lilly & Co (LLY US) has recently announced positive topline Phase 3 results for orforglipron, the GLP 1 RA drug candidate they licensed from Chugai Pharma in 2018.
- At the top dose, patients lost 7.3 kg of the 90.2 kg they weighed at the start of the trial, bettering Ozempic’s trial results.
- Once approved and commercialized, orforglipron should provide a long-term revenue visibility for Chugai Pharmaceutical (4519 JP) through milestone and royalty receipts from Lilly.
BenQ BM Pre-IPO: PHIP Updates – Performance Continues to Deteriorate
- BenQ BM Holding Cayman Corp. (BBHC HK) is looking to raise at least $US100m in its upcoming Hong Kong IPO.
- BenQ is a leading private for-profit general hospital group in mainland China, operating two general hospitals – Nanjing BenQ Hospital and Suzhou BenQ Hospital.
- In this note, we provide updates on the firm’s past performance.
D. Western Therapeutics Institute (DWTI) 4576 JP – Full Report
- SIR believes DWTI has entered an exciting new phase given significant advances in pipeline development achieved over the last 12 months.
- Key advances include: 1) publishing favorable topline results of in-house H-1337 PIIb US trials (strong prospects as “first choice as a second-line Glaucoma drug”),
- 2) commencing jointly developed Japan PII clinical trials of regenerative medicine cell therapy DWR-2206 with ActualEyes, and successfully completing all transplants
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
